SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.  20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): August 5, 2004

 

EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-21863

 

04-3030815

(State or other
jurisdiction of
incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

71 Rogers Street
Cambridge, Massachusetts 02142

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617) 250-6000

 

 



 

Item 5.           Other Events.

 

On August 5, 2004, EPIX Medical, Inc. issued a press release announcing that it has initiated its first human clinical trial of EP-2104R, an injectable MRI contrast agent which specifically targets blood clots, or thrombi, in the body.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

Item 7Financial Statements and Exhibits.

 

(c) The following exhibits are furnished with this report:

 

Exhibit Number

 

Description

 

 

 

99.1

 

Press Release dated August 5, 2004.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 
EPIX Medical, Inc.
 
(Registrant)

 

 

 

 

Date: August 5, 2004

/s/ Peyton J. Marshall

 

 

 Peyton J. Marshall

 

 Senior Vice-President,

 

 Finance and Administration,

 

 Chief Financial Officer

 

3